Premium
P2‐002: Assessment of The Safety, Tolerability, Pharmacokinetics, and Effects on Plasma and Cerebrospinal Fluid AB Peptides of AZD3293, a Novel Bace1 Inhibitor, in Healthy Japanese Adults
Author(s) -
Yoshihara Tatsuya,
Sakamoto Kei,
Matsuki Shunji,
Matsuguma Kyoko,
Uchida Naoki,
Azuma Fumihiko,
Russell Muir,
Hughes Glen,
Haeberlein Samantha Budd,
Alexander Robert C.,
Kugler Alan R.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1206
Subject(s) - tolerability , pharmacokinetics , placebo , medicine , cerebrospinal fluid , pharmacodynamics , adverse effect , dosing , biomarker , pharmacology , gastroenterology , pathology , chemistry , biochemistry , alternative medicine
POSTER PRESENTATIONS P2 P2-001 A PHARMACODYNAMIC STUDY (54861911ALZ1008)WITHABACE INHIBITOR, JNJ54861911 IN JAPANESE ASYMPTOMATIC SUBJECTS AT RISK FOR ALZHEIMER’S DEMENTIA Masayoshi Takahashi, Luc Tritsmans, Hiroko Shimizu, Tomoko Santoh, Ayako Shiraishi, Yushin Tominaga, Johannes Streffer, 1 Janssen Pharm KK Japan, Tokyo, Japan; 2 Janssen Research & Development, Beerse, Belgium. Contact e-mail: MTAKAHA4@its.jnj.com